Susceptibilidad antimicrobiana de Streptococus pneumonia colonizante de nasofaringe en ninos colombianos con neumonia
Date
1997Metadata
Show full item recordTranslated title
Antibiotic susceptability of Streptococcus pneumoniae colonizing the nasopharynx of Colombian children with pneumonia
Subject
URI
http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49891997000400002&lng=pt&nrm=isohttps://iris.paho.org/handle/10665.2/9100
Citation
Leal, Ana Lucia,Castaneda, Elizabeth (1997) Susceptibilidad antimicrobiana de Streptococus pneumonia colonizante de nasofaringe en ninos colombianos con neumonia. Rev Panam Salud Publica;1(4) -,apr. 1997. Retrieved from http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49891997000400002&lng=pt&nrm=iso
Collections
Related items
Showing items related by title, author, creator and subject.
-
Moyano Ariza, Luisa; Ochoa, Brindis; Shewade, Hemant D.; Edwards, Jeffrey K.; Trujillo Trujillo, Julián; Cuellar, Claudia M.; Rodríguez, Jaime; Hann, Katrina; Sanchez, Mauro (2023)[ABSTRACT]. Objectives. To determine the level of adherence to clinical guidelines in prescribing amoxicillin to children younger than 5 years with pneumonia in outpatient settings in Colombia from 2017 to 2019, and assess ...
-
Bastidas-Caldes, Carlos; Guerrero-Freire, Salomé; Ortuño-Gutiérrez, Nimer; Sunyoto, Temmy; Gomes-Dias, Cícero Armídio; Ramírez, Maria Soledad; Calero-Cáceres, William; Harries, Anthony D.; Rey, Joaquín; de Waard, Jacobus H.; Calvopiña, Manuel (2023)[ABSTRACT]. Objective. Colistin is an antibiotic of last resort for treating serious Gram-negative bacterial infections. However, the misuse of colistin, especially as an animal growth promoter, has contributed to increasing ...
-
Ruvinsky, Raúl O.; Rearte, Analía; Kupervaser, Judit; Gentile, Fernando; Haidar, Adriana; Cafure, Maria E.; Tito, Maria Elisa; Avaro, Federico; Cortiana, Cristina; Cozzani, Hugo; Véliz, Omar; Fossati, Sofia; Regueira, Mabel; Vizzotti, Carla (2018)[ABSTRACT]. Objective. To measure the effectiveness of pneumococcal conjugated vaccine (PCV13) against Community Acquired Pneumonia (CAP) and invasive pneumococcal disease, 2 years after the vaccine (2+1) was included into ...